Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6781 to 6795 of 7711 results

  1. Ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia [ID1548]

    Discontinued [GID-TA10416]

    Technology appraisal guidance
    Discontinued

  2. Levitronix CentriMag for treatment of refractory cardiogenic shock or severe cardiopulmonary insufficiency (discontinued)

    Discontinued [GID-MT130]

    Medical technologies guidance
    Discontinued

  3. Clinitek Microalbumin 9 reagent strips for the early detection and monitoring of kidney disease (discontinued)

    Discontinued [GID-MT163]

    Medical technologies guidance
    Discontinued

  4. Paclitaxel as albumin-bound nanoparticles with gemcitabine for adjuvant treatment of pancreatic cancer [ID1413]

    Discontinued [GID-TA10329]

    Technology appraisal guidance
    Discontinued

  5. Mogamulizumab for previously treated T-cell leukaemia-lymphoma [ID1390]

    Discontinued [GID-TA10464]

    Technology appraisal guidance
    Discontinued

  6. Niraparib for previously treated hormone-relapsed metastatic prostate cancer with DNA-repair anomalies [ID3782]

    Discontinued [GID-TA10635]

    Technology appraisal guidance
    Discontinued

  7. Atezolizumab in combination for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in people who have not received any prior systemic therapy [ID2700]

    Discontinued [GID-TA10574]

    Technology appraisal guidance
    Discontinued

  8. Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381]

    Discontinued [GID-TA10539]

    Technology appraisal guidance
    Discontinued

  9. Tisagenlecleucel for treating relapsed or refractory aggressive diffuse large B-cell lymphoma after 1 systemic therapy [ID3974]

    Discontinued [GID-TA10859]

    Technology appraisal guidance
    Discontinued

  10. Blepharitis: antimicrobial prescribing

    Discontinued [GID-NG10168]

    Antimicrobial prescribing guideline
    Discontinued

  11. Interferon beta-1b, interferon beta-1a and glatiramer acetate for the treatment of single demyelinating event with clinically isolated syndrome [ID109]

    Discontinued [GID-TAG415]

    Technology appraisal guidance
    Discontinued

  12. Bavituximab for treating non-squamous non-small-cell lung cancer after platinum-based chemotherapy [ID975]

    Discontinued [GID-TA11260]

    Technology appraisal guidance
    Discontinued

  13. Ataluren for treating cystic fibrosis in people with a CFTR gene nonsense mutation [ID955]

    Discontinued [GID-TA11262]

    Technology appraisal guidance
    Discontinued

  14. ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]

    Discontinued [GID-TA10259]

    Technology appraisal guidance
    Discontinued

  15. Nilotinib for the first line treatment of chronic myeloid leukaemia [ID79]

    Discontinued [GID-TAG408]

    Technology appraisal guidance
    Discontinued